| FUNDAMENTALS |
| MarketCap: |
0.271 mill
|
| EPS: |
-0.0200
|
| P/E: |
-0.200
|
| Earnings Date: |
May 21, 2024 |
| SharesOutstanding: |
66.00 mill
|
| Avg Daily Volume: |
0.0010 mill
|
| RATING
2024-05-03 |
|
C+
|
|
Sell
|
| RATINGS |
| Rating CashFlow: |
Sell
|
|
| Return On Equity: |
Sell
|
|
| Return On Asset: |
Neutral
|
|
| DE: |
Sell
|
|
| P/E: |
Neutral
|
|
| Price To Book: |
Strong Sell
|
|
| QUARTER GROWTHS |
|
4/21 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 |
| Revenue | | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | | n/a | n/a | n/a | n/a | n/a |
| Ebit | | n/a | n/a | n/a | n/a | n/a |
| Asset | | n/a | n/a | n/a | n/a | n/a |
| Debt | | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|
0.00x
|
|
Company: PE -0.200 | sector: PE -11.58
|
| PE RATIO: COMPANY / INDUSTRY |
|
0x
|
|
Company: PE -0.200 | industry: PE -6.21
|
| DISCOUNTED CASH FLOW VALUE |
|
N/A
|
|
N/A
|
| Expected Trading Range (DAY) |
$ 0.0041 - 0.0041
( +/- 0.00%)
|
|
ATR Model: 14 days
|
Insider Trading
| Date |
Person |
Action |
Amount |
type |
| 2024-01-02 | Ross George K | Buy | 50 000 | Common Stock |
| 2024-01-02 | Ross George K | Sell | 50 000 | Restricted Stock Units (2021 Plan) |
| 2024-01-02 | Ross George K | Sell | 50 000 | Restricted Stock Units (2021 Plan) |
| 2024-01-02 | Skelly William G | Buy | 50 000 | Common Stock |
| 2024-01-02 | Skelly William G | Sell | 50 000 | Restricted Stock Units (2021 Plan) |
| INSIDER POWER |
|
7.75
|
| Last
100 transactions |
| Buy:
88 557 065 | Sell:
8 647 538 |
Forecast:
16:00 - $0.0041
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
| Indicator Signals |
| RSI 21 |
|
| SMA |
|
| Trend |
|
| Trend 2 |
|
| Trend 3 |
|
| Volume Signals |
| Price |
$0.0041 (36.67% )
|
| Volume |
0.0003 mill
|
| Avg. Vol. |
0.0010 mill
|
| % of Avg. Vol |
24.86 %
|
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ACUR
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was incorporated in 1935 and is based in Palatine, Illinois.
The Technical Analyst
